Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Revolution Medicines (RVMD) Non Operating Income: 2019-2025

Historic Non Operating Income for Revolution Medicines (RVMD) over the last 7 years, with Sep 2025 value amounting to $10.1 million.

  • Revolution Medicines' Non Operating Income fell 48.19% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $75.3 million, marking a year-over-year decrease of 12.90%. This contributed to the annual value of $88.7 million for FY2024, which is 87.50% up from last year.
  • As of Q3 2025, Revolution Medicines' Non Operating Income stood at $10.1 million, which was down 40.55% from $16.9 million recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Non Operating Income ranged from a high of $27.3 million in Q1 2025 and a low of $221,000 during Q1 2021.
  • Over the past 3 years, Revolution Medicines' median Non Operating Income value was $18.8 million (recorded in 2023), while the average stood at $17.3 million.
  • As far as peak fluctuations go, Revolution Medicines' Non Operating Income slumped by 75.11% in 2021, and later spiked by 2,237.42% in 2023.
  • Quarterly analysis of 5 years shows Revolution Medicines' Non Operating Income stood at $237,000 in 2021, then surged by 2,042.19% to $5.1 million in 2022, then skyrocketed by 270.08% to $18.8 million in 2023, then increased by 11.70% to $21.0 million in 2024, then plummeted by 48.19% to $10.1 million in 2025.
  • Its Non Operating Income stands at $10.1 million for Q3 2025, versus $16.9 million for Q2 2025 and $27.3 million for Q1 2025.